Abstract
Genetic Engineering & Biotechnology NewsVol. 40, No. 9 TutorialBioequivalence, Bioassays, and Biowaivers: How Integrated Testing Can Accelerate Generic Drug DevelopmentAbsorption Systems shows how bioassays can support biowaiver applications by effectively demonstrating bioequivalence for complex generic drug products in vitroVatsala NaageshwaranVatsala NaageshwaranVatsala Naageshwaran, (E-mail Address: vnaageshwaran@absorption.com) is chief business officer at Absorption Systems. Website: www.absorption.com.Search for more papers by this authorPublished Online:3 Sep 2020https://doi.org/10.1089/gen.40.09.14AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 40Issue 9Sep 2020 Information© 2020 by GEN PublishingTo cite this article:Vatsala Naageshwaran.Bioequivalence, Bioassays, and Biowaivers: How Integrated Testing Can Accelerate Generic Drug Development.Genetic Engineering & Biotechnology News.Sep 2020.56-58.http://doi.org/10.1089/gen.40.09.14Published in Volume: 40 Issue 9: September 3, 2020PDF download
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
